Ionis Pharmaceuticals (IONS) Could Be 50% Undervalued As Pelacarsen Setback Resets Sentiment

Ionis Pharmaceuticals (IONS) is back in the spotlight after partner Novartis reported that the pivotal Phase 3 Lp(a)HORIZON trial of pelacarsen missed its cardiovascular outcomes goal, despite achieving its biomarker target.

The pelacarsen setback has become the clear focal point for Ionis Pharmaceuticals, with the 1-day share price return down 4.94% and the 7-day share price return down 18.02% as investors reassess pipeline risk. The year-to-date share price return has fallen 44.22%, even though the 5-year total shareholder return remains positive at 22.76%. This suggests that short-term momentum has weakened against a still constructive longer track record.

Seize this pullback in Ionis Pharmaceuticals to reassess your biotech exposure and compare it with a curated list of 16 high quality undiscovered gems that may be flying under the radar.

The selloff has reset expectations around pelacarsen and clipped confidence in the Ionis Pharmaceuticals pipeline. Does the current valuation gap now compensate you for that extra clinical risk, or does it still leave you exposed?

Most Popular Narrative: 49.5% Undervalued

Ionis Pharmaceuticals closed at $44.44, while the most widely followed narrative framework points to a fair value of $88.00. The gap investors are focusing on is how much of the clinical and launch risk is already embedded.

The rapid revenue growth and positive launch trajectory for Tryngolza in familial chylomicronemia syndrome (FCS), along with the imminent launch of Donidalorsen for HAE and multiple late-stage pipeline assets reading out or launching by 2027, are described as potential drivers of sustained, stepwise increases in top-line revenue and operating leverage as Ionis transitions from R&D-heavy to commercial-stage. Expanding addressable patient populations from rare diseases to larger segments like severe hypertriglyceridemia (sHTG), combined with favorable physician feedback and significant unmet need, is cited as a factor that could position Ionis to capture substantial market share and revenue growth from trends tied to the rise in chronic disease and an aging population.

See why 15 investors see Ionis Pharmaceuticals as 50% undervalued.

Result: Fair Value of $88.00 (UNDERVALUED)

Still, Ionis Pharmaceuticals faces real pressure if key late stage programs stumble at regulators or if broader severe hypertriglyceridemia pricing comes in lower than hoped.

Find out about the key risks to this Ionis Pharmaceuticals narrative.

Another View: What Multiples Say About Ionis Pharmaceuticals

The first take frames Ionis Pharmaceuticals as 49.5% undervalued against a fair value of $88.00, yet the market is sending mixed messages. The P/S ratio sits at 8.4x, while the fair ratio sits at 3.7x, which implies the share price could be rich relative to that benchmark.

At the same time, Ionis trades below the US Biotechs industry average P/S of 12.5x and the peer average of 12.8x. That split picture means some investors may see room for upside while others worry the stock still carries valuation risk if sentiment or forecasts reset again.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Pessimism around Ionis Pharmaceuticals after the pelacarsen news is clear, so move quickly to test the full picture and build your own stance. To stress test that view against more optimistic factors, walk through the 2 key rewards

Looking for more investment ideas beyond Ionis Pharmaceuticals?

If Ionis Pharmaceuticals has your attention, do not stop there. Use this pullback as a nudge to refresh your broader watchlist with fresh ideas.

• Target reliable upside potential by scanning a 35 high quality undervalued stocks that pairs strong business quality with prices that lag underlying fundamentals.
• Prioritize resilience in tougher markets by reviewing a 30 resilient stocks with low risk scores built around companies with sturdier financial and risk profiles.
• Hunt for future leaders early by combing through a 9 elite penny stocks with strong financials that filters for stronger balance sheets and real operating momentum.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com